X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs MYLAN (US) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   MYLAN
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
MYLAN
Dec-14
FRESENIUS KABI ONCO./
MYLAN
5-Yr Chart
Click to enlarge
High Rs1763,840-   
Low Rs792,706-   
Sales per share (Unadj.) Rs37.71,314.6-  
Earnings per share (Unadj.) Rs5.1158.4-  
Cash flow per share (Unadj.) Rs6.7254.9-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5653.5-  
Shares outstanding (eoy) m158.23378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.42.5 135.6%   
Avg P/E ratio x25.020.7 120.9%  
P/CF ratio (eoy) x18.912.8 147.4%  
Price / Book Value ratio x3.05.0 59.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,238,422 1.6%   
No. of employees `0001.225.0 4.6%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.219,896.0 26.0%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.62,396.8 29.2%   
INCOME DATA
Net Sales Rs m5,963497,400 1.2%  
Other income Rs m18-2,899 -0.6%   
Total revenues Rs m5,981494,500 1.2%   
Gross profit Rs m1,430123,706 1.2%  
Depreciation Rs m25836,532 0.7%   
Interest Rs m-2621,455 -0.1%   
Profit before tax Rs m1,21662,819 1.9%   
Minority Interest Rs m0-258 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,642 13.0%   
Profit after tax Rs m80659,920 1.3%  
Gross profit margin %24.024.9 96.4%  
Effective tax rate %28.14.2 669.1%   
Net profit margin %13.512.0 112.2%  
BALANCE SHEET DATA
Current assets Rs m5,102437,280 1.2%   
Current liabilities Rs m2,385341,866 0.7%   
Net working cap to sales %45.619.2 237.5%  
Current ratio x2.11.3 167.2%  
Inventory Days Days15078 192.2%  
Debtors Days Days113107 105.6%  
Net fixed assets Rs m5,148115,072 4.5%   
Share capital Rs m15817,589 0.9%   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,732247,257 2.7%   
Long term debt Rs m952369,377 0.3%   
Total assets Rs m10,388995,927 1.0%  
Interest coverage x-45.83.9 -1,165.4%   
Debt to equity ratio x0.11.5 9.5%  
Sales to assets ratio x0.60.5 114.9%   
Return on assets %7.58.2 91.9%  
Return on equity %12.024.2 49.4%  
Return on capital %14.613.6 107.2%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,27465,384 1.9%  
From Investments Rs m-1,204-51,563 2.3%  
From Financial Activity Rs m-196-17,229 1.1%  
Net Cashflow Rs m-126-3,408 3.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.43 Rs / USD

Compare FRESENIUS KABI ONCO. With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: GLENMARK PHARMA  CADILA HEALTHCARE  AJANTA PHARMA  MERCK LTD  LUPIN LTD  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS